spacer
The Healthcare Sales & Marketing Network celebrates 25 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Keryx Biopharmaceuticals 

 HSMN NewsFeed - 26 Oct 2021
Unicycive Therapeutics Appoints Douglas Jermasek As Executive Vice President, Corporate Strategy
Biopharmaceuticals Personnel
 HSMN NewsFeed - 10 May 2021
LogicBio Therapeutics Strengthens Management Team with Key Appointments
Regenerative Medicine Personnel
 HSMN NewsFeed - 21 Jun 2016
Keryx Biopharmaceuticals Appoints Two New Board Members
Biopharmaceuticals Personnel
 HSMN NewsFeed - 21 Jan 2014
Keryx Biopharmaceuticals Announces Appointment of Daniel W. Olmstead as Vice President, Payer Access
Biopharmaceuticals Personnel
 HSMN NewsFeed - 20 Dec 2013
Coronado Biosciences Announces Management Changes
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 Mar 2013
Keryx Biopharmaceuticals Announces Appointment of Amit Sharma, M.D. as Vice President, Medical Affairs
Biopharmaceuticals Personnel
 HSMN NewsFeed - 28 Oct 2010
Idenix Pharmaceuticals Announces Ronald C. Renaud, Jr. Named President, Chief Executive Officer and Member of the Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 21 Jul 2010
Keryx Biopharmaceuticals, Inc. Announces Appointment of Joseph Feczko, M.D. to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 14 Jul 2010
Aeterna Zentaris Announces Perifosine Has Received Orphan-Drug Designation for the Treatment of Neuroblastoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 8 Apr 2010
Aeterna Zentaris Announces Initiation of Phase 3 Registration Trial with Perifosine in Refractory Advanced Colorectal Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Apr 2010
Keryx Receives FDA Fast Track Designation for KRX-0401 (Perifosine) for the Treatment of Refractory Advanced Colorectal Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 1 Mar 2010
AEterna Zentaris Receives Positive Opinion for Orphan Medicinal Product Designation for Perifosine for the Treatment of Multiple Myeloma from the Committee for Orphan Medicinal Products of the European Medicines Agency
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 2 Dec 2009
AEterna Zentaris' Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 2 Dec 2009
Keryx Receives FDA Fast Track Designation for KRX-0401 (Perifosine) for the Treatment of Relapsed/Refractory Multiple Myeloma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 16 Sep 2009
Keryx Biopharmaceuticals Receives Orphan-Drug Designation for KRX-0401 (Perifosine) for the Treatment of Multiple Myeloma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 4 Aug 2009
Keryx Biopharmaceuticals Settles License Dispute With Alfa Wassermann
Biopharmaceuticals Licensing Litigation
 HSMN NewsFeed - 20 May 2009
Keryx Biopharmaceuticals Announces Appointment of Ron Bentsur as Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 Apr 2009
Keryx Biopharmaceuticals, Inc. Announces Michael P. Tarnok as Interim Chairman and Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 17 Feb 2009
CorNova(R) Expands Management Team with Appointment of Robert Gallahue as Chief Financial Officer
Devices Interventional Cardiology Personnel
 HSMN NewsFeed - 7 Apr 2008
Keryx Biopharmaceuticals Announces Implementation of Strategic Restructuring Plan
Biopharmaceuticals
 HSMN NewsFeed - 10 Mar 2008
Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 7 Mar 2008
Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 15 Feb 2008
Keryx Biopharmaceuticals Announces Additions to Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 11 Feb 2008
Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 6 Dec 2007
Sulodexide Data Safety Monitoring Committee Completes Additional Review of Phase 3 Study Data
Biopharmaceuticals
 HSMN NewsFeed - 26 Sep 2007
Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
Biopharmaceuticals
 HSMN NewsFeed - 17 Jul 2007
William P. Kane Named Vice President, Commercial Operations for Keryx Biopharmaceuticals, Inc.
Biopharmaceuticals Personnel
 HSMN NewsFeed - 29 Jun 2007
Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstrom's Macroglobulinemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 18 Jun 2007
Keryx Biopharmaceuticals Announces Financial Management Change
Biopharmaceuticals Personnel
 HSMN NewsFeed - 25 Apr 2007
Keryx Biopharmaceuticals Names Beth F. Levine as Senior Vice President, General Counsel & Chief Compliance Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 28 Dec 2006
The Multiple Myeloma Research Consortium (MMRC) and Keryx Biopharmaceuticals Commence Multi-Center Combination Study for the Treatment of Multiple Myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Oct 2006
Kyowa Hakko Grants Keryx Biopharmaceuticals Exclusive Rights to UCN-01, a Novel, Anticancer Agent in Phase II Clinical Development
Biopharmaceuticals Licensing
 HSMN NewsFeed - 1 Aug 2006
Keryx Biopharmaceuticals Mourns Passing of Board Member Jonathan Spicehandler, MD
Biopharmaceuticals Personnel
 HSMN NewsFeed - 2 Mar 2006
Keryx Biopharmaceuticals, Inc. Commences Phase 2, Multi-Center Study of KRX-0401 for the Treatment of Refractory Leukemia
Biopharmaceuticals
 HSMN NewsFeed - 16 Feb 2006
Keryx Biopharmaceuticals Names Ronald C. Renaud, Jr. as Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Feb 2006
Keryx Biopharmaceuticals Announces Expansion of Renal Franchise With the In-Licensing of Zerenex(TM), a Novel Phosphate Binder
Biopharmaceuticals Licensing
 HSMN NewsFeed - 4 Jan 2006
Keryx Biopharmaceuticals, Inc. Announces Appointment of Senior Pharmaceutical Executive to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Jan 2006
Keryx Biopharmaceuticals, Inc. Commences Phase II, Multi-Center Study of KRX-0401 for the Treatment of Refractory Multiple Myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Jan 2006
XTL Biopharmaceuticals Announces Appointment of Ron Bentsur as Chief Executive Officer
Biopharmaceuticals Personnel
Return to NewsFeed  

 Additional items found! 17

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 17 additional stories matching:
Keryx Biopharmaceuticals
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.